These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

280 related articles for article (PubMed ID: 6214986)

  • 1. In vitro activity of N-formimidoyl thienamycin, moxalactam, and other new beta-lactam agents against Bacteroides fragilis: contribution of beta-lactamase to resistance.
    Brown JE; Del Bene VE; Collins CD
    Antimicrob Agents Chemother; 1981 Feb; 19(2):248-52. PubMed ID: 6214986
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Influence of inoculum size on activity of cefoperazone, cefotaxime, moxalactam, piperacillin, and N-formimidoyl thienamycin (MK0787) against Pseudomonas aeruginosa.
    Corrado ML; Landesman SH; Cherubin CE
    Antimicrob Agents Chemother; 1980 Dec; 18(6):893-6. PubMed ID: 6263178
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vitro activity of MK0787 (N-formimidoyl thienamycin) and other beta-lactam compounds against Bacteroides spp.
    Nasu M; Maskell JP; Williams RJ; Williams JD
    Antimicrob Agents Chemother; 1981 Oct; 20(4):433-6. PubMed ID: 6282191
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative in vitro susceptibilities of anaerobic bacteria to cefmenoxime, cefotetan, and N-formimidoyl thienamycin.
    Owens WE; Finegold SM
    Antimicrob Agents Chemother; 1983 Apr; 23(4):626-9. PubMed ID: 6305265
    [TBL] [Abstract][Full Text] [Related]  

  • 5. N-Formimidoyl thienamycin (MK0787): in-vitro antibacterial activity and susceptibility to beta-lactamases compared with that of cefotaxime, moxalactam and other beta-lactam antibiotics.
    Hanslo D; King A; Shannon K; Warren C; Phillips I
    J Antimicrob Chemother; 1981 Jun; 7(6):607-17. PubMed ID: 6265426
    [No Abstract]   [Full Text] [Related]  

  • 6. In vitro activity of N-formimidoyl thienamycin in comparison with cefotaxime, moxalactam, and ceftazidime.
    Verbist L; Verhaegen J
    Antimicrob Agents Chemother; 1981 Mar; 19(3):402-6. PubMed ID: 6264844
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vitro activity of N-formimidoyl-thienamycin in comparison to that of moxalactam and cefotaxime against gentamicin-resistant gram-negative bacteria.
    Pusztai-Markos Z; Pranada F
    Eur J Clin Microbiol; 1982 Feb; 1(1):49-51. PubMed ID: 6293811
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vitro activity of cefbuperazone compared with that of other new beta-lactam agents against anaerobic gram-negative bacilli and contribution of beta-lactamase to resistance.
    Del Bene VE; Carek PJ; Twitty JA; Burkey LJ
    Antimicrob Agents Chemother; 1985 May; 27(5):817-20. PubMed ID: 3874597
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vitro comparative activity of moxalactam, GR 20263, and N-formimidoyl thienamycin to other beta-lactam antibiotics and tobramycin against enterobacteriaceae and staphylococci.
    Cynamon MH; Granato PA
    Chemotherapy; 1982; 28(3):204-8. PubMed ID: 6212205
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vitro susceptibility of Mycobacterium fortuitum to N-formimidoyl thienamycin and several cephamycins.
    Cynamon MH; Palmer GS
    Antimicrob Agents Chemother; 1982 Dec; 22(6):1079-81. PubMed ID: 6961887
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative activity of N-formimidoyl thienamycin with third generation cephalosporins and ureido penicillins against multiple resistant Serratia marcescens.
    Miller MA; LeFrock JL; Vercler MJ
    Microbiol Immunol; 1981; 25(11):1119-27. PubMed ID: 6276701
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A comparison of the antibacterial activities of N-formimidoyl thienamycin (MK0787) with those of other recently developed beta-lactam derivatives.
    Cullmann W; Opferkuch W; Stieglitz M; Werkmeister U
    Antimicrob Agents Chemother; 1982 Aug; 22(2):302-7. PubMed ID: 6821459
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Susceptibility of intestinal anaerobes to new beta-lactam antibiotics.
    Bansal MB; Chuah SK; Thadepalli H
    Chemotherapy; 1984; 30(4):237-43. PubMed ID: 6744975
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative in vitro activity of new beta-lactam antibiotics against anaerobic bacteria.
    Rolfe RD; Finegold SM
    Antimicrob Agents Chemother; 1981 Nov; 20(5):600-9. PubMed ID: 7325628
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Susceptibility of anaerobic bacteria to beta-lactam antibiotics and beta-lactamase production.
    Aldridge KE; Sanders CV; Lewis AC; Marier RL
    J Med Microbiol; 1983 Feb; 16(1):75-82. PubMed ID: 6218305
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antibacterial activity of N-formimidoyl thienamycin in comparison with cefotaxime, lamoxactam, cefoperazone, piperacillin gentamicin.
    Braveny I; Machka K; Elsser R
    Infection; 1982 Jan; 10(1):45-9. PubMed ID: 6279523
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In-vitro antagonism by N-formimidoyl thienamycin and cefoxitin of second and third generation cephalosporins in Aeromonas hydrophila and Serratia marcescens.
    Miller MA; Finan M; Yousuf M
    J Antimicrob Chemother; 1983 Apr; 11(4):311-8. PubMed ID: 6343337
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vitro activities of cefminox against anaerobic bacteria compared with those of nine other compounds.
    Hoellman DB; Spangler SK; Jacobs MR; Appelbaum PC
    Antimicrob Agents Chemother; 1998 Mar; 42(3):495-501. PubMed ID: 9517922
    [TBL] [Abstract][Full Text] [Related]  

  • 19. N-formimidoyl thienamycin: in vitro comparison with cefoxitin and tobramycin against clinical, bacterial isolates.
    Digranes A; Dibb WL; Benonisen E
    Acta Pathol Microbiol Immunol Scand B; 1983 Apr; 91(2):141-4. PubMed ID: 6603093
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cefoperazone against carbenicillin-resistant isolates of Pseudomonas aeruginosa: comparison with other newer cephalosporins and N-formimidoyl thienamycin.
    Chau PY; Ling J; Ng WS
    J Antimicrob Chemother; 1983 Oct; 12(4):337-45. PubMed ID: 6417100
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.